Evolutionary Genomics Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • FNAM

Stock Symbol

  • Investments
  • 1

Evolutionary Genomics General Information

Description

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Contact Information

Website
www.evolgen.com
Formerly Known As
Fona
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1026 Anaconda Drive
  • Castle Rock, CO 80108
  • United States
+1 (720)
Primary Industry
Media and Information Services (B2B)
Other Industries
Other Commercial Services
Biotechnology
Stock Exchange
OTCM
Corporate Office
  • 1026 Anaconda Drive
  • Castle Rock, CO 80108
  • United States
+1 (720)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evolutionary Genomics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
1K

Evolutionary Genomics Financials Summary

As of 31-Dec-2022, Evolutionary Genomics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 12,276 11,840
Revenue 0 0 0 12
EBITDA (913) (913) (1,755) (2,290)
Net Income (1,935) (1,935) (2,794) (1,712)
Total Assets 2,354 2,354 2,932 3,993
Total Debt 3,744 3,744 3,744 2,246
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Evolutionary Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Evolutionary Genomics‘s full profile, request access.

Request a free trial

Evolutionary Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to
Media and Information Services (B2B)
Castle Rock, CO
4 As of 2022

Basel, Switzerland
 

Whippany, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evolutionary Genomics Competitors (2)

One of Evolutionary Genomics’s 2 competitors is Syngenta, a Formerly Accelerator/Incubator backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Syngenta Formerly Accelerator/Incubator backed Basel, Switzerland
Bayer CropScience United States Formerly VC-backed Whippany, NJ
You’re viewing 2 of 2 competitors. Get the full list »

Evolutionary Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evolutionary Genomics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Evolutionary Genomics‘s full profile, request access.

Request a free trial

Evolutionary Genomics Acquisitions (1)

Evolutionary Genomics’s most recent deal was a Merger/Acquisition with Fona. The deal was made on 19-Oct-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Fona 19-Oct-2015 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Evolutionary Genomics’s complete acquisitions history, request access »

Evolutionary Genomics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Diversified Financials

Industry

Rank

Percentile

Consumer Finance

Subindustry

Rank

Percentile

To view Evolutionary Genomics’s complete esg history, request access »

Evolutionary Genomics FAQs

  • When was Evolutionary Genomics founded?

    Evolutionary Genomics was founded in 2000.

  • Where is Evolutionary Genomics headquartered?

    Evolutionary Genomics is headquartered in Castle Rock, CO.

  • What is the size of Evolutionary Genomics?

    Evolutionary Genomics has 4 total employees.

  • What industry is Evolutionary Genomics in?

    Evolutionary Genomics’s primary industry is Media and Information Services (B2B).

  • Is Evolutionary Genomics a private or public company?

    Evolutionary Genomics is a Public company.

  • What is Evolutionary Genomics’s stock symbol?

    The ticker symbol for Evolutionary Genomics is FNAM.

  • Who are Evolutionary Genomics’s competitors?

    Syngenta and Bayer CropScience United States are competitors of Evolutionary Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process